

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/164611 A1

(43) International Publication Date  
7 November 2013 (07.11.2013)

(51) International Patent Classification:  
*G01N 33/543* (2006.01)    *G01N 27/30* (2006.01)

(74) Agent: ROGERS, Alex Lee; HASELTINE LAKE LLP,  
Redcliff Quay, 120 Redcliff Street, Bristol BS1 6HU (GB).

(21) International Application Number:  
PCT/GB2013/051121

(22) International Filing Date:  
1 May 2013 (01.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
1207585.9    1 May 2012 (01.05.2012)    GB

(71) Applicants: ISIS INNOVATION LTD [GB/GB]; Ewert House, Ewert Place, Summertown, Oxford Oxfordshire OX2 7SG (GB). UNIVERSIDADE ESTADUAL PAULISTA "JULIO DE MESQUITA FILHO" [BR/BR]; Rua Quirino de Andrade, 215, Centro, 01.049-010 Sao Paulo (BR).

(72) Inventors: DAVIS, Jason; c/o Department of Chemistry, University of Oxford, Physical & Theoretical Chemistry Laboratory, South Parks Road, Oxford Oxfordshire OX1 3TA (GB). BUENO, Paulo Roberto; Universidade Estadual Paulista, R. Prof. Francisco Degni, 55, Bairro Quitandinha, 14800-900 Araraquara, 14800-060 Sao Paulo (BR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2013/164611 A1

(54) Title: AN ELECTRODE AND USE THEREOF

(57) Abstract: The application relates to an electrode for use in the electrochemical detection of a target species, wherein the electrode has a planar surface disposed on which are probe molecules that are capable of binding selectively to the target species, wherein the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 10 megaohms cm<sup>-2</sup> to 95 megaohms cm<sup>-2</sup>.

An Electrode and Use thereofField of the Invention

5 The present invention relates to an electrode for use in the electrochemical detection of target species, including, but not limited to, C-reactive protein.

Background

10 C-reactive protein (CRP) is an acute-phase protein synthesized by the liver, widely accepted as a biomarker for cardiovascular disease and inflammation (May and Wang 2007, Miller et al. 2007, Mygind et al. 2011, Pai et al. 2008). Generally, levels in plasma are less than 2.0 mg/L for healthy individuals (Vikholm-Lundin and Albers 2006), but increase up to 1000 fold during an acute phase of inflammation (Gabay and Kushner 15 1999). The American Heart Association and the United States Centre for Disease Control have suggested three categories of CRP concentration for the evaluation of cardiovascular disease risk: a CRP concentration below 1.0 mg/L representing low risk, a 1.0 to 3.0 mg/L range average risk, and levels above 3.0 mg/L representing high risk (Kushner and Sehgal 2002, Lee et al. 2011). The reliable and early quantification of 20 this target if often, then, cited as a means of improving the outcome of cardiovascular or inflammatory disease through appropriate intervention or treatment.

Currently, a number of CRP testing methods are available in clinical laboratories using turbidimetric and nephelometric technologies (Roberts et al. 2000, Roberts et al. 2001), 25 or human CRP enzyme-linked immunosorbent assay (ELISA) kits. However, these methods are generally not suitable for the clinical practice as they are either not sensitive enough, time-consuming, prone to false negatives or cost-ineffective (Pearson et al. 2004). CRP quantification methods based on surface plasmon resonance (SPR) (Hu et al. 2006, Meyer et al. 2006), piezoelectric microcantilevers 30 (Wee et al. 2005), quartz crystal microbalance technology (Kim et al. 2009), microfluidics (Lee et al. 2011) and electrochemistry (Buch and Rishpon 2008, Centi et al. 2009), have been developed during the past few years. Among these, electrochemical assays promise most in terms of low cost, flexibility and sensitivity. Electrochemical impedance spectroscopy (EIS), in particular, can sensitively monitor 35 the changes in capacitance or charge-transfer resistance associated with material

binding at specifically prepared receptive electrode surfaces and requires no prior labelling (Bogomolova et al. 2009, Rodriguez et al. 2005). In recent years a number of CRP assays by EIS have been reported. To date, however, these have been either of limited sensitivity (Vermeeren et al. 2011), not demonstrably specific (Hennessey et al. 5 2009), or to not encompass a clinically relevant range (Chen et al. 2008, Qureshi et al. 2010).

This subject-matter of this application relates to the development of a robust and highly sensitive assay for CRP in whole and dilute blood serum across the entire clinically 10 relevant range. The technique can also be applied to other markers. The interfaces are readily prepared, exhibit very good selectivity and are re-useable after assay with no apparent loss of sensitivity. We have, additionally, considered the importance of receptive layer initial resistance in subsequently observed sensitivity and demonstrated not only a clear correlation but also an ability to tune, and therefore optimise, receptive 15 film characteristics.

#### Brief Description of the Figures

Figure 1 shows Nyquist plots of different electrodes recorded in PBST (10 mM, pH 7.4) 20 solution containing 1.0 mM  $\text{Fe}(\text{CN})_6^{3-4-}$ , for (a) bare gold electrode; (b) gold electrode modified with the self-assembled monolayer; and (c) gold electrode with CRP antibody immobilized on the monolayer. The inset magnifies the high frequency region.

Figure 2 shows (A) the effect of CRP antibody immobilization time on the initial charge 25 transfer resistance,  $R_{ct}$  and sensitivity of the biosensor (the sensitivity was determined as change in  $R_{ct}$  divided by the initial  $R_{ct}$ ); and (B) the relationship between the initial  $R_{CT}$  and the sensitivity.

Figure 3 shows (A) the recorded charge-transfer resistance ( $R_{ct}$ ) of the biosensor after 30 the incubation with different concentrations of CRP protein in PBST (10 mM, pH 7.4) containing 1.0 mM  $\text{Fe}(\text{CN})_6^{3-4-}$ ; and (B) Faradaic impedance spectra corresponding to the biosensor after the incubation in PBST solution with different CRP concentrations (curves i to viii represent 0, 0.5, 1.0, 2.0, 5.0, 10, 25, and 50 nM CRP, respectively).

Figure 4 shows (A) calibration curves for the CRP biosensors performed in different solutions:

- (i) PBST (10 mM, pH 7.4) with 1.0 mM  $\text{Fe}(\text{CN})_6^{3-4-}$ ;
- (ii) PBST (10 mM, pH 7.4) with 1.0 mM  $\text{Fe}(\text{CN})_6^{3-4-}$  and 10% human blood serum;
- (iii) PBST (10 mM, pH 7.4) with 1.0 mM  $\text{Fe}(\text{CN})_6^{3-4-}$  and 20% human blood serum;

and (B) Faradaic impedance spectra corresponding to the biosensor after the incubation in PBST solution containing 1.0 mM  $\text{Fe}(\text{CN})_6^{3-4-}$  and 10% human blood serum, with different CRP concentrations (curves i to viii represent 0, 0.5, 1.0, 2.0, 5.0, 10, 25, and 50 nM CRP, respectively).

Figure 5 shows a comparison of biosensor assays of CRP in buffer solution and pure blood serum. Biosensors were incubated in CRP spiked buffer solution and pure blood serum, respectively, and impedance analyses carried out in PBST solution containing 1.0 mM  $\text{Fe}(\text{CN})_6^{3-4-}$ . Impedance levels of CRP free buffer or pure blood serum were taken as background.

Figure 6 shows the regeneration of the CRP biosensor. The biosensor was regenerated by immersing the electrode in 6 mM NaOH and 0.6% ethanol for 5 min and then washed with PBST, and the impedance measurements were taken in a solution containing PBST (10 mM, pH 7.4), 1.0 mM  $\text{Fe}(\text{CN})_6^{3-4-}$  and 10% human blood serum.

Figure 7 is a schematic illustration of the stepwise fabrication of CRP responsive EIS interfaces.

Figure 8 shows an equivalent circuit model that can be used for data fitting to determine the charge transfer resistance of an electrode as described herein.

30

### Summary of the Invention

In a first aspect, there is provided an electrode for use in the electrochemical detection of a target species, wherein the electrode has a planar surface disposed on which are

35 probe molecules that are capable of binding selectively to the target species, wherein

the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 10 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$ . In an embodiment, the target species is or comprises C-reactive protein and/or the probe molecules comprise antibodies or antibody fragments. The 5 use with other target species and probe molecules is nevertheless described below.

In an embodiment, there is provided an electrode for use in the electrochemical detection of C-reactive protein, wherein the electrode has a planar surface disposed on which are probe molecules that are capable of binding selectively to C-reactive protein, wherein the electrode prior to binding of the probe molecules with C-reactive protein 10 has an electron transfer resistance per area of the electrode of from 10 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$

In an embodiment, there is provided an electrode for use in the electrochemical detection of a target species, wherein the electrode has a planar surface disposed on 15 which are probe molecules comprising antibodies or antibody fragments that are capable of binding selectively to the target species, wherein the electrode prior to binding of the probe molecules with the target species has an electron transfer resistance per area of the electrode of from 10 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$

20 In a third aspect, there is provided a method for detecting a target species in an electrochemical impedance spectroscopy technique, wherein the method comprises contacting an electrode defined in the first aspect with a carrier medium comprising the target species, and detecting an electrical signal at the working electrode.

25 In a third aspect, there is provided an electrochemical impedance spectrometer, wherein the spectrometer comprises an electrode as defined in the first aspect.

30 In a fourth aspect, there is provided a use of an electrode according to the first aspect or an electrochemical impedance spectrometer according to the third aspect for the detection of a target species.

The present inventors have found that controlling the resistance of an electrode, which is related to the amount of coverage of a probe molecule, before binding to a target can significantly increase the sensitivity of the electrode. It has previously been assumed 35 that increasing the coverage of probe molecules on a surface would increase its

sensitivity. However, the present inventors found that keeping the coverage below certain levels (as indicated by initial resistance), increased the sensitivity of the electrode.

5

### Detailed Description

The present invention provides the first to the fourth aspects described herein. Optional and preferred features will now be described. Any of the features described herein may be combined with any of the other features described herein, unless 10 otherwise stated.

The electrode, prior to binding of the probe molecules with the target species, preferably has an electron transfer resistance per area of the electrode of 95 megaohms  $\text{cm}^{-2}$  or less. The electrode, prior to binding of the probe molecules with the 15 target species, preferably has an electron transfer resistance per area of the electrode of 10 megaohms  $\text{cm}^{-2}$  or more. The electrode, prior to binding of the probe molecules with the target species, preferably has an electron transfer resistance per area of the electrode of from 10 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$ .

20 Optionally, the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 20 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$ , optionally an electron transfer resistance per area of the electrode of from 40 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$ , optionally an electron transfer resistance per area of the electrode of from 50 megaohms  $\text{cm}^{-2}$  to 95 25 megaohms  $\text{cm}^{-2}$ , optionally an electron transfer resistance per area of the electrode of from 55 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$ .

Electron transfer resistance, sometimes termed the charge transfer resistance, can be 30 measured using known techniques. In an embodiment, the electron transfer resistance is determined by using an electrochemical impedance spectrometer to obtain impedance information about the electrode, and using an ideal Randles equivalent circuit, which includes the charge transfer resistance as an element of the circuit. Such a Randles equivalent circuit is described, for example, in Vyas RN, Li KY, Wang B. 2010. Modifying Randles Circuit for Analysis of Polyoxometalate Layer-by-Layer Films. 35 Journal of Physical Chemistry B 114: 15818-15824, which is incorporated herein by

reference. An example of an ideal Randles equivalent circuit is illustrated in Figure 8. In this figure,  $R_{ct}$  represents the charge (or electron) transfer resistance,  $Z_w$  represents the Warburg impedance,  $R_s$  is the solution resistance (sometimes denoted  $R_{sol}$ ), and  $C_{dl}$  is the capacitance between the electrode surface and ions in the liquid carrier medium (this is sometimes denoted  $C_{surf}$ ). Fitting impedance data to a circuit to obtain electron (or charge) transfer resistance is known to the skilled person. It is described in many publications, including, but not limited to, *Electroanalysis* 19, 2007, No. 12, 1239-1257 (an article entitled *Label-free Impedance Biosensors: Opportunities and Challenges*, authored by Daniels, et al), which is incorporated herein by reference in its entirety, and references cited therein. Commercial software is available for circuit fitting, for example “Fit and Simulation version 1.7” software available from Autolab, The Netherlands, which may accompany a frequency resolved analyser module of an EIS spectrometer (e.g. also available from Autolab, The Netherlands).

15 The electron transfer resistance per area of the electrode is determined by dividing the charge transfer resistance of the electrode by the area of the electrode (having the probe molecules thereon). This area may be determined using known techniques. In an embodiment, the area of the electrode is the effective surface area of the electrode, which can be calculated by taking the area of a cathodic peak in coulombs and

20 applying the relationship  $A = \frac{Q}{482 \mu\text{C cm}^{-2}}$ , where A is the effective area of the electrode, and Q is the area of the cathodic peak in colombs (see, for example, Hoogvliet, J. C.; Dijksma, M.; Kamp, B.; van Bennekom, W. P. *Anal Chem* 2000, 72, 2016, which is incorporated herein by reference in its entirety), and dividing the charge transfer resistance ( $R_{ct}$ ) by the effective area.

25

The electrode may comprise any electrically conducting material. The working electrode may comprising a metal or carbon. The metal may be a metal in elemental form or an alloy of a metal. Optionally, the whole of the electrode comprises a metal or

30 carbon. The electrode may comprise a transition metal. The electrode may comprise a transition metal selected from any of groups 9 to 11 of the Periodic Table. The electrode may comprise a metal selected from, but not limited to, rhenium, iridium, palladium, platinum, copper, indium, rubidium, silver and gold. The electrode may comprise a metal selected from gold, silver and platinum. The electrode may comprise

a carbon-containing material, which may be selected from edge plane pyrolytic graphite, basal plane pyrolytic graphite, glassy carbon, boron doped diamond, highly ordered pyrolytic graphite, carbon powder and carbon nanotubes.

5 In a preferred embodiment, the electrode comprises gold.

The surface of the electrode is planar, which includes a generally flat surface, typically without indentations, protrusions and pores. Such electrode surfaces can be prepared, before probe molecules and any associated linker molecules are bound to the surface, 10 by techniques such as polishing with fine particles, e.g. spraying with fine particles, optionally in a sequence of steps where the size of the fine particles is decreased in each polishing step. The fine particles may, for example, comprise a carbon-based material, such as diamond, and/or may have particles with diameters of 10 µm or less, optionally 5 µm or less, optionally 3 µm or less, optionally 1 µm or less, optionally 0.5 15 µm or less, optionally 0.1 µm or less. Following polishing, the electrode surface may be washed, e.g. ultrasonically, optionally in a suitable liquid medium, such as water, e.g. for a period of at least 1 minute, e.g. from about 1 minute to 10 minutes. Optionally, the electrode surface may be washed with an abrasive, e.g. acidic, solution, for example following the polishing and, if used, ultrasonic washing steps. The 20 abrasive solution may comprise an inorganic acid, e.g. H<sub>2</sub>SO<sub>4</sub>, and/or a peroxide, e.g. H<sub>2</sub>O<sub>2</sub>, in a suitable liquid medium, e.g. water. Optionally, the electrodes can be electrochemically polished, which may follow any steps involving one or more of polishing with fine particles, washing e.g. ultrasonically and/or using an abrasive solution. The electrochemical polishing may involve cycling between an upper and 25 lower potential until a stable reduction peak is reached, e.g. an upper potential of 0.5 V or more, optionally 1 V or more, optionally 1.25 V or more, and a lower potential of 0.5 V or less, optionally 0.25 V or less, optionally 0.1 V or less.

The probe molecules are capable of binding selectively to a target species, which may 30 be or comprise C-reactive protein. Other target species are described below. The probe molecule preferably comprises a binding species selected from an antibody, an antibody fragment, an aptamer, an oligosaccharide, a peptide, and a protein. Preferably, the probe molecules comprise a binding species selected from one or more of an antibody, a nucleic acid and a peptide. The binding species is capable of binding

to the target species, e.g. C-reactive protein. The probe moieties bind selectively to the target species, e.g. C-reactive protein.

If the probe molecules comprise an antibody or an antibody fragment, the antibody or 5 the antibody fragment may be selected from one or more of the classes IgA, IgD, IgE, IgG and IgM. In a preferred embodiment, the antibody or antibody fragment is of the IgG type. The antibody binds selectively to the target species. The antibody or antibody fragment may be derived from a mammal, including, but not limited to, a mammal selected from a human, a mouse, a rat, a rabbit, a goat, a sheep, and a 10 horse. In an embodiment, the probe molecules comprise an antibody of the IgG type derived from a goat.

If the probe molecules comprise an aptamer, the aptamer may be selected from a peptide aptamer, a DNA aptamer and a RNA aptamer.

15 The target species may be selected from, but is not limited to, proteins, polypeptides, antibodies, nanoparticles, drugs, toxins, harmful gases, hazardous chemicals, explosives, viral particles, cells, multi-cellular organisms, cytokines and chemokines, 20 ganglionocyte, organelles, lipids, nucleic acid sequences, oligosaccharides, chemical intermediates of metabolic pathways and macromolecules. In preferred embodiments, the target species comprises, consists essentially of, or consists of, a biological molecule, more suitably a biological macromolecule, most suitably a polypeptide.

If the target species is or comprise a protein, the protein may be selected from, but is 25 not limited to, native proteins, denatured proteins, protein fragments, and prokaryotically or eukaryotically expressed proteins. Protein may have its normal meaning in the art, and most preferably 'protein' refers to a polypeptide molecule. Such polypeptide may comprise modifications such as glycosylation; phosphorylation or other such modifications.

30 If the target species is an antibody, the antibody may be selected from one or more of the classes IgA, IgD, IgE, IgG and IgM.

If the target species is a nanoparticle, the nanoparticle can be selected from, but is not 35 limited to, one or more of insulating, metallic or semiconducting nanoparticles.

If the target species is a drug, the drug may be selected from, but is not limited to, alcohol (e.g. ethanol), amphetamines, amyl nitrate, heroin, ketamine, anabolic steroids, LSD, solvents, cannabis, cocaine (such as cocaine hydrochloride or 'coke'), tobacco, 5 tranquilisers, crack (i.e. cocaine free base), ecstasy and/or gammhydroxybutyrate (GHB). Alternatively, in some embodiments, the drug may be a medicinal substance.

The target species may be a candidate drug, e.g. a chemical or biological entity which may be tested or screened for a particular activity or property using the present 10 invention.

If the target species is a toxin, the toxin may be selected from, but is not limited to, one or more toxins originating from animals, plants, or bacteria.

15 If the target species is a viral particle, the viral particle may be selected from, but is not limited to, one or more viral particles with and without a genome.

If the target species is a cell, the cell may be selected from, but is not limited to, one or 20 more of pluripotent progenitor cells, human cells (e.g. B-cells, T-cells, mast cells, phagocytes, neutrophils, eosinophils, macrophages, endothelial cells), cancerous cells (e.g. those originating from liver, cervical bone, pancreatic, colorectal, prostate, epidermal, brain, breast, lung, testicular, renal, bladder cancers), unicellular organisms of non-human origin, algae, fungi, bacteria, plant cells, parasite eggs, plasmodia and mycoplasma.

25

If the target species is an organelle, the organelle may be selected from, but is not limited to, one or more of nucleus, mitochondria, Golgi apparatus, endoplasmic reticulum, lysosome, phagosome, intracellular membranes, extracellular membranes, cytoskeleton, nuclear membrane, chromatin, nuclear matrix and chloroplasts.

30

If the target species is a lipid, the lipid may be selected from, but is not limited to, one or more of signalling lipids, structural lipids, phospholipids, glycolipids and fatty acids.

If the target species is nucleic acid sequence, the nucleic acid sequence may be selected from, but is not limited to, one or more of DNA, cDNA, RNA, rRNA, mRNA, miRNA and tRNA.

5 If the target species is an oligosaccharide, the oligosaccharide may be selected from, but is not limited to, one or more of oligosaccharides of human, animal, plant, fungal or bacterial origin.

10 In a preferred embodiment, the target species is a protein. The method and other aspects of the invention may be used for the detection or identification of a proteins.

The target species may be any antigen or analyte that is indicative of a particular disease. The target may be selected from, for example, C-reactive protein, angiotensin I converting enzyme (peptidyl-dipeptidase A) 1; adiponectin; advanced glycosylation 15 end product-specific receptor; alpha-2-HS-glycoprotein; angiogenin, ribonuclease, RNase A family, 5; apolipoprotein A-I; apolipoprotein B (including Ag(x) antigen); apolipoprotein E; BCL2-associated X protein; B-cell CLL/lymphoma 2; complement C3; chemokine (C-C motif) ligand 2; CD 14, soluble; CD 40, soluble; cdk5;, pentraxin-related; cathepsin B; dipeptidyl peptidase IV; Epidermal growth factor; endoglin; Fas; 20 fibrinogen; ferritin; growth hormone 1; alanine aminotransferase; hepatocyte growth factor; haptoglobin; heat shock 70kDa protein 1 B; intercellular adhesion molecule 1; insulin-like growth factor 1 (somatomedin C); insulin-like growth factor 1 receptor; insulin-like growth factor binding protein 1; insulin-like growth factor binding protein 2; insulin-like growth factor-binding protein 3; interleukin 18; interleukin 2 receptor, alpha; 25 interleukin 2 receptor, beta; interleukin 6 (interferon, beta 2); interleukin 6 receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); interleukin 8; activin A; leptin (obesity homolog, mouse); plasminogen activator, tissue; proopiomelanocortin (adrenocorticotropin/ beta-lipotropin/ alpha-melanocyte stimulating hormone/ beta-melanocyte stimulating hormone/ beta-endorphin); proinsulin; resistin; selectin e 30 (endothelial adhesion molecule 1 ); selectin P (granule membrane protein 140kDa, antigen CD62); serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1 ), member 1; serum/glucocorticoid regulated kinase; sex hormone-binding globulin; transforming growth factor, beta 1 (Camurati-Engelmann disease); TIMP metallopeptidase inhibitor 2; tumor necrosis factor receptor superfamily, member 35 1 B; vascular cell adhesion molecule 1 (VCAM-1 ); vascular endothelial growth factor;

Factor II, Factor V, Factor VIII, Factor IX, Factor XI, Factor XII, F/fibrin degradation products, thrombin-antithrombin III complex, fibrinogen, plasminogen, prothrombin, and von Willebrand factor and the like. Markers useful for diabetes include for example C-reactive protein; glucose; insulin; TRIG; GPT; HSPA1 B; IGFBP2; LEP; ADIPOQ; 5 CCL2; ENG; HP; IL2RA; SCp; SHBG; and TIMP2.

The target species may be a target associated with monitoring diabetes. In an embodiment, the target may be selected from glucose, insulin, Interleukin 2 receptor alpha (IL2-RA), C-reactive protein (CRP) and glycated hemoglobin (HbA1c). If the 10 target is glucose, the probe moieties may be selected from, for example, the molecular recognition element of GDH-FAD assay or a glucose/galactose binding protein ("GGBP") (Scholle, et al., Mol. Gen. Genet. 208:247-253 (1987)). If the target is IL-2RA, the probe moieties may comprise or consist of a monoclonal antibody specific for IL-2RA. If the target species is or comprises C-reactive protein, preferably this is 15 human C-reactive protein.

As indicated above, preferably, the probe molecules comprise a binding species selected from one or more of an antibody, a nucleic acid and a peptide. The binding 20 species may be directly attached to the surface of the electrode or attached to the surface of the electrode via a linker species. If a linker species is present on the surface of the electrode, preferably the linker species forms a self-assembling monolayer.

25 The electrode as described herein may be formed by forming a self-assembling monolayer of linker species, optionally activating the linker species, and then binding the binding species to at least some of the linker species.

30 Preferably, the electrode surface having the probe molecules thereon, as a whole, is selective for the target species. If the electrode surface having the probe molecules thereon is selective for the target species, this indicates that substantially only or only the target species will bind to the surface (binding to the probe molecules), and other species (e.g. present in the carrier medium with the target species) will not bind, or not bind to any significant degree, to other parts of the electrode surface or other species 35 thereon. For example, the electrode surface may comprise a self-assembling

monolayer of linker molecules, some of which are bound to probe moieties, e.g. antibodies, that selectively bind to a target (e.g. C-reactive protein). When in a liquid carrier medium, e.g. blood, the electrode surface preferably only binds to the target species, not to other species present in the liquid carrier medium. Such selective 5 electrode surfaces may be termed highly selective electrode surfaces.

In an embodiment, the probe molecule is of the formula A—L—B, where A is a moiety that binds to the surface of the electrode, L is a linker moiety and B is a moiety which binds to the target species, e.g. C-reactive protein.

10

'A' may be selected from an appropriate binding group, depending on the nature of the material of the electrode. A may be selected from, but is not limited to, biotin, hydrazine, alkynyl, alkylazide, amino, hydroxyl, carboxy, thio, aldehyde, phosphoinothioester, maleimidyl, succinyl, succinimidyl, isocyanate, ester, strepavidin, 15 avidin, neuavidin, and biotin binding proteins. If the electrode comprises a noble material, e.g. gold, silver or platinum, A is preferably thio, which may be selected from —SH and —S-. If the electrode comprises a metal that has a layer of oxide on its surface, e.g. copper, A may be a carboxy group.

20

L may be any species that covalently links A with B. L is preferably a species that allows formation of a self-assembling monolayer. L may comprise an alkylene moiety comprising at least 2 carbons, the alkylene moiety being directly attached to A; optionally the alkylene moiety is a straight-chain alkylene moiety. L may comprise an alkylene moiety comprising at least 10 carbons, optionally from 10 to 30 carbons, 25 optionally from 10 to 20 carbons, optionally from 11 to 15 carbon atoms, and the alkylene moiety is optionally a straight-chain alkylene moiety, and the alkylene moiety is directly attached to A.

30

In an embodiment, L is of the formula  $-(CH_2)_n(-O-CH_2-CH_2-)_m-D-$ , wherein n is from 1 to 30 and m is from 0 to 10 and D is a group that binds to B. D may be selected from a single bond,  $-(C=O)-$ ,  $-OCH_2-(C=O)-$ ,  $-(C=O)-NH-$ ,  $-(C=O)-O-$ ,  $-OCH_2-(C=O)-NH-$ ,  $-OCH_2-(C=O)-OH-$ ,  $-O-$ ,  $-NH-$ . n may be from 10 to 20. m may be 1 to 5, optionally 2 to 4, optionally 3. Optionally, if D is any one of the species  $(C=O)-NH-$ ,  $-(C=O)-O-$

-OCH<sub>2</sub>-(C=O)-NH-, -OCH<sub>2</sub>-(C=O)-O-, -O- and -NH-, then -NH- or -O- in these species may be derived from a probe molecules, e.g. antibody, prior to being bound to the linker species L.

5

B may be selected from a binding species as described above, for example selected from an antibody, an antibody fragment, an aptamer, an oligosaccharide, a peptide, a protein. Such species that bind selectively to target species, e.g. C-reactive protein, are available commercially, e.g. goat anti-human CRP polyclonal antibody, which is 10 available from AbD Serotec.

In an embodiment, A—L— is a species of the formula thio-(CH<sub>2</sub>)<sub>n</sub>-(-O-CH<sub>2</sub>-CH<sub>2</sub>-)<sub>m</sub>-D-, wherein n is from 1 to 30 and m is from 0 to 10 and D is a group that binds to B; optionally n, m and D may be as defined above, and thio is selected from -S- and HS-.

15

In an embodiment, A—L— is a species of the formula thio-(CH<sub>2</sub>)<sub>n</sub>-(-O-CH<sub>2</sub>-CH<sub>2</sub>-)<sub>m</sub>-D-, wherein n is from 1 to 30 and m is from 0 to 10 and D is a group that binds to B; optionally n, m and D may be as defined above, and thio is selected from -S- and HS-.

20

In an embodiment, A—L— is a species of the formula thio-(CH<sub>2</sub>)<sub>n</sub>-(-O-CH<sub>2</sub>-CH<sub>2</sub>-)<sub>m</sub>-D-, wherein n is from 1 to 30 and m is from 0 to 10 and D is a group that binds to B; optionally n, m and D may be as defined above, and thio is selected from -S- and HS-.

25

B is preferably capable of binding selectively to the target species, e.g. C-reactive protein. B preferably comprises or is a binding species selected from an antibody, an antibody fragment, an aptamer, an oligosaccharide, a peptide, and a protein. B preferably comprises or is a binding species selected from one or more of an antibody, an antibody fragment, a nucleic acid and a peptide. Preferably, the probe moieties bind selectively to C-reactive protein.

30

If B comprises or is an antibody or an antibody fragment, the antibody or the antibody fragment may be selected from one or more of the classes IgA, IgD, IgE, IgG and IgM. The antibody or antibody fragment preferably binds selectively to C-reactive protein.

If B comprises or is an aptamer, the aptamer may be selected from a peptide aptamer, a DNA aptamer and a RNA aptamer.

In an embodiment, an electrode as described herein, e.g. having probe molecules thereon, may be produced by providing the electrode having the planar surface, then forming a self-assembling monolayer of linker species on the planar surface, and attaching probe moieties, e.g. antibodies, that bind to the target species to at least some of the linker species. The linker species may optionally be activated, e.g. by reaction with an activator, such as N-hydroxysuccinimide (NHS), to allow for facile attachment of the probe moieties to the linker species. In an embodiment, the linker species forming the self-assembling monolayer are of the formula A—L, wherein A is a moiety that binds to the surface of the electrode, L is a linker moiety capable of binding to a moiety (which may be denoted B) which binds to the target species, e.g. an antibody. In an embodiment, A may be as defined above, and the linker species L forming the monolayer, prior to binding to the probe moieties, is of the formula  $-(\text{CH}_2)_n-(\text{O}-\text{CH}_2-\text{CH}_2)_m-\text{D}-$ , wherein n is from 1 to 30 and m is from 0 to 10 and D is a group that binds to B. D may be selected from a single bond,  $-(\text{C}=\text{O})-\text{H}$ ,  $-(\text{C}=\text{O})\text{OH}$   $-\text{OCH}_2-(\text{C}=\text{O})\text{H}$ ,  $-\text{OCH}_2-(\text{C}=\text{O})\text{OH}$ ,  $-(\text{C}=\text{O})-\text{NH}_2$ ,  $-\text{OCH}_2-(\text{C}=\text{O})-\text{NH}_2$ ,  $-\text{OCH}_2-(\text{C}=\text{O})-\text{OH}$ ,  $-\text{OH}$ ,  $-\text{NH}_2$ .

20

The present application also relates to a method for detecting a target species (including, but not limited to, C-reactive protein) in an electrochemical impedance spectroscopy technique, wherein the method comprises contacting an electrode defined in the first aspect with a carrier medium comprising the target species 25 (including, but not limited to, C-reactive protein), and detecting an electrical signal at the working electrode.

Electrochemical impedance spectroscopy (EIS) is known to the skilled person. Generally, a varying ac potential is applied on a bias (or DC) potential between a 30 working electrode and a counter electrode. Generally, EIS involves scanning across a range of ac frequencies. The ratio of the input signal (typically the varying potential) to the output signal (typically the varying current) allows the impedance to be calculated. There is generally a phase difference between the input signal and the output signal, such that the impedance can be considered as a complex function, having a real part 35 (sometimes termed  $Z'$ ) and an imaginary part (sometimes termed  $Z''$ ). The real and

imaginary parts of impedance can be plotted against one another, e.g. in the form of a Nyquist plot, as illustrated in Figure 1. By fitting the impedance data to an assumed equivalent circuit, the electron transfer resistance can be determined. In the present application, as mentioned above, an ideal Randles equivalent circuit can be used to 5 determine the electron transfer resistance. The frequency range of the varying ac potential applied may be from 0.05 Hz to 10 kHz. The amplitude of the applied ac potential, which is typically in the form of a sine wave, may be from 1 mV to 100 mV, optionally from 5 mV to 50 mV, optionally from 5 mV to 20 mV, optionally from 5 mV to 10 mV, optionally 8 mV to 12 mV, optionally about 10 mV. The bias potential (or direct 10 current potential) may be set at any desired potential. If a redox probe is present in the carrier medium, the bias potential may be set at the electrode potential of the redox probe under the conditions at which the method is carried out.

A redox probe may be present in the carrier medium. The redox probe may be a 15 transition metal species, wherein the transition metal can adopt two valence states (e.g. a metal ion (M) being able to adopt M(II) and M(III) states). In an embodiment, the redox probe contains a metal ion, wherein the metal of the metal ion is selected from iron, ruthenium, iridium, osmium, cobalt, tungsten and molybdenum. In an embodiment, the redox probe is selected from  $\text{Fe}(\text{CN})_6^{3-4-}$ ,  $\text{Fe}(\text{NH}_3)_6^{3+2+}$ ,  $\text{Fe}(\text{phen})_3^{3+2+}$ , 20  $\text{Fe}(\text{bipy})_2^{3+2+}$ ,  $\text{Fe}(\text{bipy})_3^{3+2+}$ ,  $\text{Ru}^{3+2+}$ ,  $\text{RuO}_4^{3-2-}$ ,  $\text{Ru}(\text{CN})_6^{3-4-}$ ,  $\text{Ru}(\text{NH}_3)_6^{3+2+}$ ,  $\text{Ru}(\text{en})_3^{3+2+}$ ,  $\text{Ru}(\text{NH}_3)_5(\text{Py})^{3+2+}$ ,  $\text{Ir}^{4+3+}$ ,  $\text{Ir}(\text{Cl})_6^{2-3-}$ ,  $\text{Ir}(\text{Br})_6^{2-3-}$ ,  $\text{Os}(\text{bipy})_2^{3+2+}$ ,  $\text{Os}(\text{bipy})_3^{3+2+}$ ,  $\text{OxCl}_6^{2-3-}$ , 25  $\text{Co}(\text{NH}_3)_6^{3+2+}$ ,  $\text{W}(\text{CN})_6^{3-4-}$ ,  $\text{Mo}(\text{CN})_6^{3-4-}$ , optionally substituted ferrocene, polyferrocene, quinones, such as p-benzoquinone and hydroquinone and phenol. In an embodiment, the redox probe is an iron-containing species in which iron is in Fe(II) and/or Fe(III) 30 states. In an embodiment, the redox probe is  $\text{Fe}(\text{CN})_6^{3-4-}$ . The redox probe may be present in the carrier medium an amount of from 0.1 mM to 100 mM, optionally from 0.5 mM to 10 mM, optionally from 0.5 mM to 2 mM, optionally from 0.5 mM to 1.5 mM, optionally about 1 mM.

30 The carrier medium is preferably in liquid form. The carrier liquid may be any liquid in which the target species (including, but not limited to, C-reactive protein) can be suspended or dissolved. In an embodiment, the carrier liquid comprises water. In an embodiment, the carrier liquid comprises a biological fluid. A biological fluid may be a fluid that has been obtained from a subject, which may be a human or an animal. In an 35 embodiment, the carrier liquid comprises an undiluted biological fluid. An undiluted

biological fluid in the present context is a biological fluid obtained from a subject, e.g. a human or animal, that has not been diluted with another liquid, although additives such as a redox probe, may be present in the undiluted biological fluid. The biological fluid may be selected from blood, urine, tears, saliva, sweat, and cerebrospinal fluid.

5

Optionally, the carrier medium comprises a biological fluid obtained from a subject, e.g. a human or animal, and a diluent. The diluent may be added to the biological fluid after it has been obtained from the subject. The diluent may include a liquid medium, e.g. a liquid medium selected from water and an alcohol, e.g. an alkanol, e.g. ethanol. The 10 carrier medium may further comprise a buffer. The buffer may comprise a phosphate.

The method may comprise calculating the concentration of the target species (e.g. C-reactive protein) from the electrical signal. The electrical signal may be converted into impedance data and then converted to the concentration of the target species (e.g. C-reactive protein) from the electrical signal. The electrical signal may be converted into charge transfer resistance data and then converted to the concentration of the target species (e.g. C-reactive protein) from the electrical signal. The method may involve comparing the data obtained in the electrochemical impedance spectroscopy technique, e.g. from the electrical signal, the impedance data or the charge transfer 20 resistance data, and comparing the data with data obtained in a calibration step, to obtain the concentration of the target species (e.g. C-reactive protein). The method may involve an initial calibration step that determines a relationship between the concentration of the target species (e.g. C-reactive protein) and electrochemical data obtained from the electrochemical signal in the electrochemical impedance 25 spectroscopy technique; the electrochemical data may be selected from impedance data and charge transfer resistance data; the relationship may be used to convert the electrochemical data obtained from a sample of interest in the electrochemical impedance spectroscopy technique to the concentration of the target species (e.g. C-reactive protein) in the sample.

30

The concentration of the target species (e.g. C-reactive protein) in the carrier medium may be 0.1 nM or more, optionally 0.16 nM or more, optionally 0.2 nM or more, optionally 0.5 nM or more. The concentration of the target species (e.g. C-reactive protein) in the carrier medium may be 100 nM or less, optionally 80 nM or less, 35 optionally 50 nM or less, optionally 10 nM or less. The concentration of the target

species (e.g. C-reactive protein) in the carrier medium may be from 0.1 nM to 100 nM, optionally from 0.16 nM to 100 nM, optionally from 0.16 nM to 50 nM.

The concentration of the target species (e.g. C-reactive protein) in the carrier medium  
5 may be 10 µg/L or more, optionally 15 µg/L or more, optionally 19 µg/L or more, optionally 20 µg/L or more, optionally 0.1 mg/L or more, optionally 1 mg/L or more, optionally 3 mg or more. The concentration of the target species (e.g. C-reactive protein) in the carrier medium may be 100 mg/L or less, optionally 80 mg/L or less, optionally 50 mg/L or less, optionally 30 mg/L or less. The concentration of the target  
10 species (e.g. C-reactive protein) in the carrier medium may be from 10 µg/L to 100 mg/L, optionally from 19 µg/L to 100 mg/L, optionally from 19 µg/L to 50 mg/L.

The calculating may comprise one or more comparisons of the electrical signal with the electrical signal of an ideal equivalent circuit.

15

The present inventors have found that they can regenerate the electrode, that has been bound to target species (e.g. C-reactive protein), by dissociating bound target species (e.g. C-reactive protein) from the electrode. The method may involve, after the contacting of the electrode with the target species (e.g. C-reactive protein), such that  
20 the target species (e.g. C-reactive protein) is bound to the probe molecules, and detecting the electrical signal, dissociating the target species (e.g. C-reactive protein) from the probe molecules. The dissociating may comprise contacting of the electrode surface having target species (e.g. C-reactive protein) thereon with an alkali liquid medium, e.g. an alkali aqueous liquid medium, optionally having a pH of 8 or more,  
25 optionally a pH of 9 or more, optionally a pH of 10 or more, optionally a pH of 11 or more, optionally a pH of 8 to 12, optionally a pH of 9 to 12. The alkali liquid medium may contain a basic substance. The basic substance is preferably soluble in water. The basic substance may be selected from, but not limited to, a metal hydroxide, a metal carbonate, ammonia. The metal of the metal hydroxide or metal carbonate may  
30 be selected from Group 1 and Group 2 of the Periodic Table.

The present invention also relates to an electrochemical impedance spectrometer, wherein the spectrometer comprises an electrode as defined herein. The electrochemical impedance spectrometer may be of a standard design. The  
35 electrochemical impedance spectrometer may comprise an electrode of the first aspect

as a working electrode, a counter electrode, and, if desired a reference electrode. The electrochemical impedance spectrometer preferably comprises a means for applying, controlling and varying a potential between the working and counter electrodes, and a means for measuring the resultant current. The electrochemical impedance spectrometer preferably comprises a potentiostat for controlling the potential and measuring the resultant current. The electrochemical impedance spectrometer preferably comprises a means for calculating impedance data from the potential applied and the resultant current. The electrochemical impedance spectrometer may comprise a means for calculating electron transfer resistance of the working electrode.

10

The present invention also relates to the use of an electrode as described herein or an electrochemical impedance spectrometer as described herein for the detection of a target species, e.g. C-reactive protein. The use may include detecting the presence of and/or detecting the concentration of the target species, e.g. C-reactive protein.

15

Examples

In the examples below, human CRP, human blood serum and bovine serum albumin (5 BSA) were purchased from Sigma Aldrich. The goat anti-human CRP polyclonal antibody was purchased from AbD Serotec. 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) were purchased from Sigma Aldrich. Polyethylene glycol (PEG) thiol HS-C<sub>11</sub>-(EG)<sub>3</sub>-OCH<sub>2</sub>-COOH was purchased from Prochimia Surfaces, Poland. Ultrapure water (18.2 MΩ/cm) was obtained from a 10 Milli-Q system and used throughout. Phosphate buffered saline (PBS) with Tween-20 (PBST, 10 mM, pH 7.4) was prepared by dissolving PBS tablets (Sigma Aldrich) in water with 0.2% v/v Tween-20 added, and filtered using a 0.22 μm membrane filter. All other chemicals were of analytical grade.

15 *2.2. Apparatus*

Electrochemical experiments were performed on an Autolab Potentiostat 12 equipped with an FRA2 module (Metrohm Autolab B.V.). A conventional three-electrode system with a gold disk working electrode (1.6mm diameter, BASi), platinum wire counter electrode and a silver/silver chloride (Ag/AgCl) reference electrode (CH Instruments) 20 were used. All potentials are reported relative to this reference. CRP stock solution concentrations were calculated via the UV absorbance at 280 nm (Motie et al. 1996) using a Shimadzu UV spectrometer (Shimadzu Scientific Instruments).

*2.3. Surface preparation*

25 Gold electrodes were firstly polished with 3.0, 1.0 and 0.1 μm diamond spray (Kemet International Ltd) in sequence and ultrasonically washed in water for about 5 min prior to immersion in freshly prepared piranha solution (concentrated H<sub>2</sub>SO<sub>4</sub>: H<sub>2</sub>O<sub>2</sub>, v/v 3:1. Caution: this must be handled with extreme care!) for 15 min. Electrodes were then 30 electrochemically polished by potential cycling (CV) between -0.1 and 1.25 V until a stable reduction peak was obtained. The effective surface area of the gold electrode can be calculated at this point by taking the area of the cathodic peak in coulombs and

$$A = \frac{Q}{482 \mu\text{C cm}^{-2}}$$

applying the relationship (Hoogvliet et al. 2000), and the reported charge transfer resistance (R<sub>ct</sub>) was normalized by this.

(1) Hoogvliet, J. C.; Dijksma, M.; Kamp, B.; van Bennekom, W. P. *Anal Chem*  
5 2000, 72, 2016.

Pre-treated gold electrodes were then dried in a flow of nitrogen gas and immediately immersed in a 10 mM solution of HS-C<sub>11</sub>H<sub>22</sub>-(EG)<sub>3</sub>-OCH<sub>2</sub>-COOH in ethanol for 16 hours 10 at room temperature. The biocompatible (Cho et al. 2011, Klapshina et al. 2010) and antifouling properties (Harder et al. 1998, Schilp et al. 2009) of such films are sufficient to enable specific assessments to be made in complex biological fluid. After SAM formation gold surfaces were rinsed with ethanol then water and dried in a flow of nitrogen gas prior to incubation in a solution containing 0.4 M EDC and 0.1 M NHS for 15 15 minutes (terminal carboxyl group activation) and then 10 µM CRP antibody solution (PBST, pH 7.4) for 1 hour (Figure 7), unless stated otherwise.

#### 2.4. *Electrochemical impedance spectroscopy*

EIS spectra were recorded across a 0.05 Hz to 10 kHz frequency range. The amplitude 20 of the applied sine wave potential was 10 mV with the direct current potential set at 0.25 V (the E<sub>0</sub> of the redox probe used, 1.0 mM Fe(CN)<sub>6</sub><sup>3-/4-</sup>). Data was acquired in 10 mM PBST solution, plotted in the form of complex plane diagrams (Nyquist plots), and fitted through an ideal Randles equivalent circuit (Vyas et al. 2010), asas illustrated in 25 Figure 8. In this figure, R<sub>ct</sub> represents the charge (or electron) transfer resistance, Z<sub>w</sub> represents the Warburg impedance, R<sub>s</sub> is the solution resistance, and C<sub>dl</sub> is the capacitance between the electrode surface and target species or ions in the liquid 30 carrier medium. The raw impedance data is acquired by a FRA (frequency resolved analyser) module (in this case manufactured by Autolab, The Netherlands), then fit to the equivalent circuit in Figure 8 using inbuilt software ("Fit and Simulation version 1.7"). The software runs multiple iterations of fittings to reduce errors then outputs values for all equivalent circuit components, including R<sub>ct</sub>.

Assays were carried out by electrode incubation in CRP spiked PBST, specific dilutions 35 of blood serum or whole blood serum at room temperature for 30 min each. In the first two cases PBST was pre-doped with redox probe. EIS responses were normally

recorded in the same incubation solution, with the exception of the whole (undiluted) blood serum tests, where the electrodes were rinsed with PBST after incubation prior to assessment in PBST containing 1.0 mM  $\text{Fe}(\text{CN})_6^{3-/\text{4}-}$ . To initially evaluate interfacial selectivity BSA was used. Used surfaces were regenerated using 6 mM NaOH and 5 0.6% ethanol for 5 min (Albrecht et al. 2008) prior to PBST washing.

### 3. Results and discussion

#### 3.1. Biosensor fabrication and initial impedance

EIS presents a useful means of characterising the stepwise fabrication of a receptive 10 surface. In Nyquist plots, the semicircles at low sampling frequency report on charge transfer restrictions imposed sterically or electrostatically as films are constructed. Predictably, there are sharp increases in  $R_{\text{CT}}$  as the receptor layer is fabricated.  $R_{\text{ct}}$  15 specifically increases from less than 4.5 k $\Omega$ /cm $^2$  to  $\sim$ 45 M $\Omega$ /cm $^2$  after the formation of the PEG SAM and further upwards on antibody immobilisation (Figure 1). The 20 resistance of the interface thereafter responds in a calibratable manner to target protein binding.

The present inventors found that the initial resistance of an electrode, i.e. before 25 binding to CRP, plays a role in subsequently observed sensitivity. This initial resistance is directly tuneable through the antibody surface density. This is itself controllable through either incubation time or incubation concentration as the layer is constructed. Figure 2 summarises the observed trend in assay sensitivity with initial 30 layer charge transfer resistance. Notably, as the antibody surface coverage decreases (as the immobilization timeframe is reduced from 70 min to 10 min), assay sensitivity initially increases in magnitude by up to 400% (and the limit of detection decreases 35 consequently) before falling presumably as the density of surface bound and functional antibodies falls below the point where specific target binding is effective (in terms of probability). These observations are robust and reproducible across numerous assays.

#### 30 3.2. Detection of CRP in buffer

The prepared interfaces were subsequently used to screen CRP in PBST. From the progressive and then saturating increases in  $R_{\text{CT}}$  with concentration (Figure 3), a dissociation constant  $K_D$  of  $1.1 \pm 0.11$  nM, can be derived, a value in excellent 35 agreement with a previous differential pulse voltammetry determination with the same polyclonal antibody (Hennessey et al. 2009).

Prior to saturation,  $R_{CT}$  reports linearly with logarithmic sensitivity on CRP concentration across a 0.5-50 nM range (equivalent to 60 µg/L to 6.0 mg/L) with a limit of detection (LOD) of  $176 \pm 18$  pM. This low detection limit (equating to  $\sim 19$  µg/L) confirms sensitivity to be comfortably sufficient for practical application and is married to a assay range encompassing that which is clinically relevant. This range, taken with its associated detection limit, exceeds the clinical relevance of any prior reported CRP assay to the best of our knowledge. The prepared interfaces are, additionally, unresponsive (<3% change in signal) to BSA levels of up to 100 nM.

10

### 3.3. Detection of CRP in the blood serum

From a point of care perspective, the direct and facile assessment of CRP in blood serum is necessary. In any label free assay, however, this is exceedingly demanding. Though a number of amperometric or sandwich based EIS immunoassay methods have been demonstrated (Balkenhohl and Lisdat 2007a, b, Pan et al. 2010, Rosales-Rivera et al. 2011, Tran et al. 2011), to the best of our knowledge, there exists no prior report of a non-amplified and label free impedance assays that has been reported as being effective in undiluted complex biological media.

20 Being confident about the degree of control we had over our electrode interfaces and in the light of the low levels of response to even high levels of BSA, we screened here for CRP in blood serum in two ways. In the first instance, *in situ* assessments were made with CRP spiked blood serum at controllable dilution in PBST (Figure 4). Under such circumstances reliable linear assessments were possible across the clinically relevant 25 range with an LOD of  $262 \pm 28$  pM at serum concentrations of up to 10% v/v.

30 Subsequent analyses were carried out with CRP spiked undiluted blood serum; Resistance optimized sensor electrodes were incubated in these solutions for 15 minutes and then measured after rinsing with PBST. As is evident in Figure 5, the sensor response in such analyses is markedly close (in the higher concentration range of most clinical relevance, 10-50 nM, the differences are < 3%) to that observed in spiked PBST. This enables analysis to be performed in whole blood serum across the CRP concentration range required for useful cardiovascular disease risk assessment. From a practical perspective, these assays can be carried out with as little as 5 µL of

undiluted blood serum and report quantitatively within 10 min. The utilised electrode interfaces are also, subsequently, reusable (see below).

#### 3.4. Biosensor regeneration

5 Surface regeneration was achieved with high fidelity (see figure 6) by immersion of used surfaces in 6 mM NaOH and 0.6% ethanol for 5 min (to disassociate the CRP antibody-antigen complex) and then washing with PBST. We believe the robust regeneration is possible partially because of the absence of the BSA passivation commonly employed at such immunoassaying surfaces. The interfaces herein could be  
10 reused without significant detriment of the assay (97% of the original interface response retained over 7 regenerations). This regeneration is effective for assays carried out in PBS, diluted serum or whole serum.

15 The present inventors have found an optimised and reusable electrochemical label free biosensor capable of the reliable detection of CRP across the clinically relevant range in dilute or whole blood serum. The *in situ* determined polyclonal antibody binding affinity maps very well onto previous determinations at comparable interfaces. In addition to facilitating high assay sensitivity and selectivity, the prepared biosensor interfaces also exhibited satisfying reusability. In optimising the initial interfacial  
20 resistance through antibody surface density, assay sensitivity can be markedly increased.

Assays such as these are easily integrated into portable and multiplexed formats capable of sampling just a few  $\mu$ L of biological fluid within minutes. We believe the  
25 presented results serve as an important basis for the development of convenient point of care analysis of a marker (i.e. CRP) long considered as a sensitive probe of infection, trauma, inflammation and cardiac risk.

#### References

30 Albrecht C, Kaeppel N, Gauglitz G. 2008. Two immunoassay formats for fully automated CRP detection in human serum. Analytical and Bioanalytical Chemistry 391: 1845-1852.

Balkenhol T, Lisdat F. 2007a. Screen-printed electrodes as impedimetric immunosensors for the detection of anti-transglutaminase antibodies in human sera.  
35 Analytica Chimica Acta 597: 50-57.

Balkenhol T, Lisdat F. 2007b. An impedimetric immunosensor for the detection of autoantibodies directed against gliadins. *Analyst* 132: 314-322.

Bogomolova A, Komarova E, Reber K, Gerasimov T, Yavuz O, Bhatt S, Aldissi M. 2009. Challenges of Electrochemical Impedance Spectroscopy in Protein Biosensing.

5 Analytical Chemistry 81: 3944-3949.

Buch M, Rishpon J. 2008. An Electrochemical Immunosensor for C-Reactive Protein Based on Multi-Walled Carbon Nanotube-Modified Electrodes. *Electroanalysis* 20: 2592-2594.

10 Centi S, Sanmartin LB, Tombelli S, Palchetti I, Mascini M. 2009. Detection of C Reactive Protein (CRP) in Serum by an Electrochemical Aptamer-Based Sandwich Assay. *Electroanalysis* 21: 1309-1315.

Chen XJ, Wang YY, Zhou JJ, Yan W, Li XH, Zhu JJ. 2008. Electrochemical impedance immunosensor based on three-dimensionally ordered macroporous gold film. *Analytical Chemistry* 80: 2133-2140.

15 Cho HY, et al. 2011. Synthesis of Biocompatible PEG-Based Star Polymers with Cationic and Degradable Core for siRNA Delivery. *Biomacromolecules* 12: 3478-3486.

Gabay C, Kushner I. 1999. Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation. *New England Journal of Medicine* 340: 448-454.

20 Harder P, Grunze M, Dahint R, Whitesides GM, Laibinis PE. 1998. Molecular conformation in oligo(ethylene glycol)-terminated self-assembled monolayers on gold and silver surfaces determines their ability to resist protein adsorption. *Journal of Physical Chemistry B* 102: 426-436.

Hennessey H, Afara N, Omanovic S, Padjen AL. 2009. Electrochemical investigations of the interaction of C-reactive protein (CRP) with a CRP antibody chemically 25 immobilized on a gold surface. *Analytica Chimica Acta* 643: 45-53.

Hoogvliet JC, Dijksma M, Kamp B, van Bennekom WP. 2000. Electrochemical pretreatment of polycrystalline gold electrodes to produce a reproducible surface roughness for self assembly: A study in phosphate buffer pH 7.4. *Analytical Chemistry* 72: 2016-2021.

30 Hu WP, Hsu HY, Chiou A, Tseng KY, Lin HY, Chang GL, Chen SJ. 2006. Immunodetection of pentamer and modified C-reactive protein using surface plasmon resonance biosensing. *Biosensors & Bioelectronics* 21: 1631-1637.

Kim N, Kim DK, Cho YJ. 2009. Development of indirect-competitive quartz crystal microbalance immunosensor for C-reactive protein. *Sensors and Actuators B-Chemical*

35 143: 444-448.

Klapshina LG, Douglas WE, Grigoryev IS, Ladilina EY, Shirmanova MV, Mysyagin SA, Balalaeva IV, Zagaynova EV. 2010. Novel PEG-organized biocompatible fluorescent nanoparticles doped with an ytterbium cyanoporphyrazine complex for biophotonic applications. *Chemical Communications* 46: 8398-8400.

5 Kushner I, Sehgal AR. 2002. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? *Archives of Internal Medicine* 162: 867-869.

Lee WB, Chen YH, Lin HI, Shiesh SC, Lee GB. 2011. An integrated microfluidic system for fast, automatic detection of C-reactive protein. *Sensors and Actuators B-Chemical* 157: 710-721.

10 May A, Wang TJ. 2007. Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin. *Expert Review of Molecular Diagnostics* 7: 793-804.

Meyer MHF, Hartmann M, Keusgen M. 2006. SPR-based immunosensor for the CRP detection - A new method to detect a well known protein. *Biosensors & Bioelectronics* 21: 1987-1990.

15 Miller VM, Redfield MM, McConnell JP. 2007. Use of BNP and CRP as biomarkers in assessing cardiovascular disease: Diagnosis versus risk. *Current Vascular Pharmacology* 5: 15-25.

Motie M, Brockmeier S, Potempa LA. 1996. Binding of model soluble immune 20 complexes to modified C-reactive protein. *Journal of Immunology* 156: 4435-4441.

Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, Gotze JP, Johansen JS, Kastrup J, Grp CT. 2011. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. *Inflammation Research* 60: 281-287.

25 Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. 2008. C-Reactive Protein (CRP) Gene Polymorphisms, CRP Levels, and Risk of Incident Coronary Heart Disease in Two Nested Case-Control Studies. *Plos One* 3.

Pan Y, Sonn GA, Sin MLY, Mach KE, Shih MC, Gau V, Wong PK, Liao JC. 2010. 30 Electrochemical immunosensor detection of urinary lactoferrin in clinical samples for urinary tract infection diagnosis. *Biosensors & Bioelectronics* 26: 649-654.

Pearson TA, Mensah GA, Hong YL, Smith SC. 2004. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease - Application to Clinical and Public Health Practice - Overview. *Circulation* 110: E543-E544.

Qureshi A, Gurbuz Y, Kallempudi S, Niazi JH. 2010. Label-free RNA aptamer-based capacitive biosensor for the detection of C-reactive protein. *Physical Chemistry Chemical Physics* 12: 9176-9182.

Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. 2000. Evaluation of four 5 automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. *Clinical Chemistry* 46: 461-468.

Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, Rifai N. 2001. Evaluation of nine automated high-sensitivity c-reactive protein methods: Implications for clinical and epidemiological applications. Part 2. *Clinical Chemistry* 47: 10 418-425.

Rodriguez MC, Kawde AN, Wang J. 2005. Aptamer biosensor for label-free impedance spectroscopy detection of proteins based on recognition-induced switching of the surface charge. *Chemical Communications*: 4267-4269.

Rosales-Rivera LC, Acero-Sanchez JL, Lozano-Sanchez P, Katakis I, O'Sullivan CK. 15 2011. Electrochemical immunosensor detection of antigliadin antibodies from real human serum. *Biosensors & Bioelectronics* 26: 4471-4476.

Schilp S, Rosenhahn A, Pettitt ME, Bowen J, Callow ME, Callow JA, Grunze M. 2009. 20 Physicochemical Properties of (Ethylene Glycol)-Containing Self-Assembled Monolayers Relevant for Protein and Algal Cell Resistance. *Langmuir* 25: 10077-10082.

Tran DT, Vermeeren V, Grieten L, Wenmackers S, Wagner P, Pollet J, Janssen KPP, Michiels L, Lammertyn J. 2011. Nanocrystalline diamond impedimetric aptasensor for the label-free detection of human IgE. *Biosensors & Bioelectronics* 26: 2987-2993.

Vermeeren V, Grieten L, Vanden Bon N, Bijnens N, Wenmackers S, Janssens SD, 25 Haenen K, Wagner P, Michiels L. 2011. Impedimetric, diamond-based immunosensor for the detection of C-reactive protein. *Sensors and Actuators B-Chemical* 157: 130-138.

Vikholm-Lundin I, Albers WM. 2006. Site-directed immobilisation of antibody fragments for detection of C-reactive protein. *Biosensors & Bioelectronics* 21: 1141-1148.

Vyas RN, Li KY, Wang B. 2010. Modifying Randles Circuit for Analysis of 30 Polyoxometalate Layer-by-Layer Films. *Journal of Physical Chemistry B* 114: 15818-15824.

Wee KW, Kang GY, Park J, Kang JY, Yoon DS, Park JH, Kim TS. 2005. Novel 35 electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers. *Biosensors & Bioelectronics* 20: 1932-1938.

## CLAIMS

1. An electrode for use in the electrochemical detection of a target species, wherein  
5 the electrode has a planar surface disposed on which are probe molecules that are capable of binding selectively to the target species, wherein the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 10 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$ .
- 10 2. An electrode according to claim 1, wherein the target species comprises or is C-reactive protein.
3. An electrode according to claim 1 or claim 2, wherein the probe molecules comprise or are antibodies and/or antibody fragments.
- 15 4. An electrode according to claim 3, wherein the antibodies or antibody fragments are of a class selected from IgG, IgA, IgD, IgE and IgM.
5. An electrode according to any one of the preceding claims, wherein the electrode  
20 prior to binding of the probe molecules with the target species has an electron transfer resistance per area of the electrode of from 55 megaohms  $\text{cm}^{-2}$  to 95 megaohms  $\text{cm}^{-2}$ .
6. An electrode according to any one of the preceding claims, wherein the electrode prior to binding of the probe molecules with the target species has an electron transfer  
25 resistance per area of the electrode of from 65 megaohms  $\text{cm}^{-2}$  to 90 megaohms  $\text{cm}^{-2}$ .
7. An electrode according to any one of the preceding claims, wherein the electrode prior to binding of the probe molecules with the target species has an electron transfer resistance per area of the electrode of from 75 megaohms  $\text{cm}^{-2}$  to 85 megaohms  $\text{cm}^{-2}$ .
- 30 8. An electrode according to any one of the preceding claims, wherein the electrode comprises a transition metal.

9. An electrode for use according to claim 8, wherein the electrode comprises a metal selected from gold, rhenium, iridium, palladium, platinum, copper, indium, rubidium and silver.

5 10. An electrode according to any one of the preceding claims, wherein the probe molecule is of the formula A—L—B, where A is a moiety that binds to the surface of the electrode, L is a linker moiety and B is a moiety which binds selectively to the target species.

10 11. An electrode according to claim 10, wherein A is selected from biotin, hydrazine, alkynyl, alkylazide, amino, hydroxyl, carboxy, thiol, aldehyde, phosphoinothioester, maleimidyl, succinyl, succinimidyl, isocyanate, ester, strepavidin, avidin, neuavidin, and biotin binding proteins.

15 12. An electrode according to claim 10 or claim 11, wherein L comprises a hydrocarbon moiety.

13. An electrode according to any one of claims 10 to 12, wherein L comprises an alkylene moiety comprising at least 10 carbons.

20 14. An electrode according to any one of claims 10 to 13, wherein L is of the formula  $-(\text{CH}_2)_n(-\text{O}-\text{CH}_2-\text{CH}_2-)_m-\text{D}-$ , wherein n is from 1 to 30 and m is from 0 to 10 and D is a group that binds to B.

25 15. An electrode according to claim 14, wherein D is selected from a single bond,  $-(\text{C}=\text{O})-$ ,  $-\text{OCH}_2-(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{O})-\text{NH}-$ ,  $-(\text{C}=\text{O})-\text{O}-\text{OCH}_2-(\text{C}=\text{O})-\text{NH}-$ ,  $-\text{OCH}_2-(\text{C}=\text{O})-\text{O}-$ ,  $-\text{O}-$  and  $-\text{NH}-$ .

30 16. An electrode according to any one of claims 10 to 15, wherein B is selected from an antibody, an antibody fragment, an aptamer, an oligosaccharide, a peptide and a protein.

17. A method for detecting a target species in an electrochemical impedance spectroscopy technique, wherein the method comprises contacting an electrode as

defined in any one of claims 1 to 16 with a carrier medium comprising the target species, and detecting an electrical signal at the working electrode.

18. A method according to claim 17, wherein the target species is or comprises C-  
5 reactive protein.

19. A method according to claim 17 or claim 18, wherein the carrier medium comprises a biological fluid.

10 20. A method according to claim 19, wherein the biological fluid is selected from blood, urine, tears, saliva, sweat, and cerebrospinal fluid.

21. A method according to claim 19 or claim 20, wherein the biological fluid is an undiluted biological fluid.

15 22. A method according to any one of claims 17 to 21, wherein the carrier medium further comprises a redox probe.

20 23. A method according to any one of claims 17 to 22, wherein the method additionally comprises calculating the concentration of C-reactive protein from the electrical signal.

24. A method according to any one of claims 17 to 23, the method additionally comprising, after contacting of the contacting of the electrode with the carrier medium  
25 comprising the target species, such that the target species is bound to the probe molecules, dissociating the target species from the probe molecules.

25. A method according to claim 24, the method comprises, after dissociating the target species from the probe molecules, reusing the electrode in an electrochemical  
30 method.

26. An electrochemical impedance spectrometer, wherein the spectrometer comprises an electrode as defined in any one of claims 1 to 16.

30

27. The use of an electrode according to claim 1 to 16 or an electrochemical impedance spectrometer according to claim 26 for the detection of C-reactive protein.




Fig. 1




Fig. 2




Fig. 3




Fig. 4






Fig. 5

**Fig. 6**



**Fig. 7**




Fig. 8

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB2013/051121

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. G01N33/543 G01N27/30  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, PAJ, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	<p>A. JOHNSON ET AL.: "Sensitive affimer and antibody based impedimetric label-free assays for C-reactive protein.", ANALYTICAL CHEMISTRY, vol. 84, 10 July 2012 (2012-07-10), pages 6553-6560, XP055066974, ACS Publications Washington DC USA the whole document</p> <p>-----</p> <p style="text-align: center;">-/-</p>	1-27

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier application or patent but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 June 2013	18/07/2013
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Van Bohemen, Charles

## INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2013/051121

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	TH. BRYAN ET AL.: "An optimised electrochemical biosensor for the label-free detection of C-reactive protein in blood", BIOSENSORS AND BIOELECTRONICS, vol. 39, no. 1, 15 January 2013 (2013-01-15), pages 94-98, XP002698946, Elsevier, Amsterdam the whole document -----	1-27
A	J.Y. PARK ET AL.: "Label-Free Detection of Antibody-Antigen Interactions on (R)-Lipo-diaza-18-crown-6 Self-Assembled Monolayer Modified Gold Electrodes", ANALYTICAL CHEMISTRY, vol. 80, 2008, pages 4986-4993, XP002698947, Washington DC USA figure 6 -----	1-27
A	WO 2011/069997 A2 (ITI SCOTLAND LTD [GB]) 16 June 2011 (2011-06-16) page 20, line 12 - page 21, line 8; claim 9 -----	1-27
1		

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No

PCT/GB2013/051121

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2011069997 A2	16-06-2011	CN 102753965 A EP 2510342 A2 JP 2013513790 A US 2012285829 A1 WO 2011069997 A2	24-10-2012 17-10-2012 22-04-2013 15-11-2012 16-06-2011